Cranial Technologies Brings FDA-Cleared DOC Band® Infant Head Reshaping Treatment to China Following NMPA Approval
Key Insights
Cranial Technologies (search) officially launched its DOC Band® (search) treatment in China at the China International Import Expo, marking the company's first entry into the Chinese market after treating over 400,000 infants globally.
The DOC Band® (search) is the first FDA-cleared medical device designed to treat plagiocephaly (search) (flat head syndrome (search)), using proprietary 3D imaging and AI-based design technology to create custom-fitted cranial orthotics for each infant.
Research indicates approximately 25 percent of infants may require clinical intervention for plagiocephaly (search), presenting a significant market opportunity in China where awareness of the condition is increasing.
Cranial Technologies (search), a leading US medical device company, officially introduced its flagship DOC Band® (search) treatment to the Chinese market at the China International Import Expo (CIIE) in Shanghai, marking a significant milestone in the company's global expansion strategy. The company, which has treated over 400,000 infants across the United States and Europe, received clearance from China's National Medical Products Administration (search) (NMPA) for its innovative infant head reshaping technology.
Market Entry Strategy and Clinical Need
The company's entry into China comes at a time of increasing awareness of plagiocephaly (search), commonly known as flat head syndrome (search), among Chinese newborns. According to research cited by the company, approximately 25 percent of infants may require clinical intervention for this condition, a ratio consistent with observations in international markets.
"We are truly honored to participate in CIIE for the first time — it is one of the world's most influential platforms for global trade and innovation," said Debbie James, Chief Executive Officer of Cranial Technologies (search). "CIIE provides an opportunity to establish meaningful partnerships that can help bring world-class infant care solutions to more Chinese families. Our mission aligns closely with the objectives of Healthy China 2030, making this an ideal time to begin a deeper dialogue with this important market."
Advanced Technology and Customization
The DOC Band® (search) represents the first FDA-cleared medical device specifically designed to gently reshape an infant's head as the baby grows. The treatment utilizes the company's proprietary 3D imaging and AI-based design technology to create custom-fitted solutions that address each infant's unique cranial needs.
"Each band is custom-made to meet the individual needs of every baby — like snowflakes, no two are the same," James explained. This personalized approach reflects the company's commitment to precision medicine in pediatric care, ensuring optimal outcomes for each patient.
Implementation and Training Infrastructure
To support the successful launch in China, Cranial Technologies (search) has developed a comprehensive implementation strategy that includes a dedicated e-learning platform for Chinese clinicians, supported by the company's American training team. "Our success relies on a combination of advanced product design and comprehensive clinical protocols," James noted.
The company plans to adopt a partnership-based business model, collaborating with local distributors, physicians, and hospitals to deliver its treatment across China. This approach aims to ensure proper integration of the technology within the existing healthcare infrastructure while maintaining the high standards of care that have characterized the company's operations in other markets.
Company Background and Global Experience
Founded in 1986, Cranial Technologies (search) developed the DOC Band® (search) in 1998 as the first FDA-cleared cranial orthotic for treating plagiocephaly (search). The company's extensive experience spans nearly four decades, during which it has established itself as a global leader in the treatment of infant head shape conditions. The successful treatment of over 400,000 babies worldwide demonstrates the clinical efficacy and safety profile of the DOC Band® system.
The product's availability in the Chinese market is expected to begin soon following the NMPA clearance, potentially addressing a significant unmet medical need in pediatric care within the region.